| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.26 | 8.3% | 44.4% |
| Total Income | 0.26 | 8.3% | 44.4% |
| Expenditure | 20.31 | 26.5% | 40.9% |
| PBT | -19.42 | 28.6% | 50.0% |
| Net Profit | -19.42 | 28.6% | 49.9% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.54 | 14.9% | 28.6% |
Vistagen Therapeutics Reports Q2 FY2026 Results
04 May 2026 · 4 May, 7:17 am
Summary
The press release announces Vistagen Therapeutics, Inc.'s financial results for the second quarter of fiscal year 2026, which ended on September 30, 2025. The press release was issued on November 13, 2025. No specific financial details or performance metrics are provided in the text.
Informational and educational content only. Not investment advice.